Clinical Trials · NCT01203306
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- University of Turin, Italy
- Enrollment
- 42
- Start date
- Jan 2006
- Locations
- 5 sites, Italy
- Primary endpoint
- time to progression